이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dimerix 대차 대조표 상태

재무 상태 기준 확인 5/6

Dimerix 의 총 주주 지분은 A$1.7M 이고 총 부채는 A$1.4M, 이는 부채 대 자기자본 비율을 83.2% 로 가져옵니다. 총자산과 총부채는 각각 A$15.1M 및 A$13.4M 입니다.

주요 정보

83.2%

부채 비율

AU$1.43m

부채

이자 보상 비율	n/a
현금	AU$14.81m
주식	AU$1.72m
총 부채	AU$13.37m
총 자산	AU$15.09m

최근 재무 상태 업데이트

Recent updates

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dec 19

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Jul 05

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Feb 17

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Jun 02

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01

재무 상태 분석

단기부채: DXB 의 단기 자산 ( A$15.1M )이 단기 부채( A$3.1M ).

장기 부채: DXB 의 단기 자산( A$15.1M )이 장기 부채( A$10.3M ).

부채 대 자본 내역 및 분석

부채 수준: DXB 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: DXB 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 83.2% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 수익성이 없는 DXB 현재의 플러스 무료 현금 흐름 수준을 유지한다면 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: DXB 은(는) 수익성이 없지만 잉여 현금 흐름이 양수이고 22.7 % 감소하더라도 3년 이상 충분한 현금 활주로를 보유하고 있습니다. 년도.

Dimerix 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Is Dimerix (ASX:DXB) Using Too Much Debt?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Recent updates

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

New major risk - Share price stability

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.20

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.46

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기